Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790544 | 0.87 | GAA (0.48) | GAAKMT2ANR1H2MEN1VCAM1 | |
| SCHEMBL18950887 | 0.86 | GAA (0.47) | GAAKMT2ANR1H2MEN1VCAM1 | |
| SCHEMBL18950793 | 0.83 | GAA (0.53) | GAAKMT2AMEN1LMNA | |
| SCHEMBL17171725 | 0.82 | VCAM1 (0.51) | GAAKMT2AMEN1VCAM1MAPT | |
| SCHEMBL17176997 | 0.82 | GAA (0.52) | GAAKMT2AMEN1LMNA | |
| SCHEMBL17546523 | 0.82 | GAA (0.43) | GAAKMT2ANR1H2MEN1VCAM1 | |
| SCHEMBL19114595 | 0.82 | VCAM1 (0.46) | GAAKMT2ANR1H2VCAM1 | |
| SCHEMBL18950885 | 0.82 | GAA (0.40) | GAAKMT2AMEN1VCAM1LMNA | |
| SCHEMBL19114979 | 0.81 | GAA (0.43) | GAAKMT2ANR1H2MEN1VCAM1 | |
| SCHEMBL17171743 | 0.81 | VCAM1 (0.36) | GAAKMT2AVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777138-B2 | Latent additive and composition containing latent additive | ADEKA CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20170198117-A1 | ANTIOXIDANT FOR THERMOPLASTIC RESIN AND THERMOPLASTIC RESIN COMPOSITION CONTAINING SAME | ADEKA CORPORATION (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3178905-A1 | ANTIOXIDANT FOR THERMOPLASTIC RESIN AND THERMOPLASTIC RESIN COMPOSITION INCLUDING SAME | Adeka Corporation (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-20150291772-A1 | LATENT ADDITIVE AND COMPOSITION CONTAINING LATENT ADDITIVE | ADEKA CORPORATION (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291772-A1 | LATENT ADDITIVE AND COMPOSITION CONTAINING LATENT ADDITIVE | TCF7L2, LUC7L2, TLL2 | GAA 2583/4885KMT2A 2013/4885NR1H2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.